PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations

Journal of the National Cancer Institute

Volumn 108, Issue 3, 2016, Pages

  Pharoah, Paul D P ^a   Song, Honglin ^a   Dicks, Ed ^a   Intermaggio, Maria P ^b   Harrington, Patricia ^a   Baynes, Caroline ^a,c,d,e   Alsop, Kathryn ^c   Bogdanova, Natalia ^f,g   Cicek, Mine S ^h   Cunningham, Julie M ^h   Fridley, Brooke L ⁱ   Gentry Maharaj, Aleksandra ^j   Hillemanns, Peter ^f   Lele, Shashi ^k   Lester, Jenny ^l   McGuire, Valerie ^m   Moysich, Kirsten B ^k   Poblete, Samantha ^k   Sieh, Weiva ^m   Sucheston Campbell, Lara ^k   Widschwendter, Martin ^j   Whittemore, Alice S ^m   Dörk, Thilo ^f   Menon, Usha ^j   Odunsi, Kunle ^k   Goode, Ellen L ^h   Karlan, Beth Y ^l   Bowtell, David D ^c,n,o   Gayther, Simon A ^b,l   Ramus, Susan J ^b   Wozniak, E ^c,d,e   Ryan, A ^c,d,e   Ford, J ^c,d,e   Balogun, N ^c,d,e   Mack, Marie ^c,d,e   Luccarini, Craig ^c,d,e   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g National Medical Center Mother and Child   (Belarus)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 2C;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MOSAICISM; ONCOGENE; OVARY CARCINOMA; PPM1D GENE; PRIORITY JOURNAL; PYROSEQUENCING; SOMATIC MUTATION; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MOSAICISM; MUTATION; OVARIAN NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; POLYMERASE CHAIN REACTION;

EID: 84962612922     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv347     Document Type: Article

References (13)

1. Ruark E, Snape K, Humburg P, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013; 493(7432):406-410.
2. Akbari MR, Lepage P, Rosen B, et al. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst. 2014; 106(1):djt323 doi:10.1093/jnci/djt323.
3. Bookman MA. Molecular wanderings through the DNA damage response and risk for ovarian cancer. J Natl Cancer Inst. 2014;106(1):djt350 doi:10.1093/ jnci/djt350.
4. Ramus SJ, Harrington P, Pye C, et al. The contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mut. 2007;28:(12);1207-1215.
5. Pharoah PD, Tsai YY, Ramus SJ, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4);362-370.
6. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703-4709.
7. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589-595.
8. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
9. Hofstetter G1, Concin N, Braicu I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma-analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131(1):15-20.
10. Mahner S, Eulenburg C, Staehle A, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49(1):142-149.
11. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-689.
12. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76-83.
13. Narod S. Response. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst. 2014;106(4):dju045 doi:10.1093/jnci/ dju045.